Burrard Pharmaceuticals Enterprises Ltd., Vancouver, Canada, supports importers, distributors, and local marketing-authorisation holders seeking metformin finished-dose supply through a partner-site model.
Email bd@burrardpharma.com with your company, territory, and finished-dose supply, dossier support, or both.
Burrard does not manufacture in-house. Manufacture for this programme is placed with a qualified partner GMP site named under CDA.
Site GMP evidence is shared in the quality pack under CDA. Site GMP is not product approval.
This page discusses the INN metformin. Glucophage is named for identification only and is not a Burrard trademark or a Burrard-branded good.
Metformin is a biguanide in the established oral class used in type 2 diabetes.
Oral solid, strengths confirmed under CDA.
Fixed-dose combinations, including sitagliptin/metformin, other combinations, and salts not named on this page, are out of scope unless separately confirmed under CDA. Immediate-release versus extended-release is not chosen here.
Say whether the interest is metformin alone. Do not use this address to ask for a metformin combination and expect it to be read as the same SKU. Company, territory, and finished-dose supply, dossier support, or both are enough to open the file.
Scope table. Public copy only. Strengths, packs, stability, and dossier status are confirmed under CDA, not on this page.
| INN | Metformin |
| Dosage form | Oral solid, strengths confirmed under CDA |
| Strengths | Confirmed under CDA / quality pack |
| Pack sizes | Confirmed under CDA / quality pack |
| Stability / climate zone | Not stated. Confirmed under CDA. |
| Dossier format | Not asserted. Confirmed under CDA if a file is offered. |
| Facility class | Named site, in the quality pack. |
| WHO prequalification | Not claimed |
| Bioequivalence | Not claimed |
| MOQ / Incoterms | Confirmed under CDA |
| Exclusivity note | Long off-patent generic. Not a claim that every salt, release profile, or country is clear. |
Burrard coordinates metformin finished-dose supply for commercial partners. Manufacture is at a qualified partner GMP site named under CDA, not at a Burrard plant. The reader is a partner, not a patient. This page is not a dose and not a superiority claim. Price and pack count are not published. The order of work is the quality pack, then site and batch evidence under CDA, then a short supply call.
The pack is a B2B qualification file. It is not a marketing authorisation and not a patient leaflet.
GMP or API documents describe the named site or the API. They are not Burrard product approval in the United States, the European Union, Canada, or elsewhere. This page claims no FDA, EMA, or Health Canada product approval and no country-of-origin marketing authorisation. The local MAH or importer holds the destination authorisation.
Metformin is a long off-patent generic. It has been commercially sold as a generic oral solid for decades. That is all this page says about exclusivity. It does not say every extended-release patent, every combination patent, or every country is clear. Sitagliptin/metformin is a separate programme with its own dated US fact, and that fact is not reused here.
Burrard discusses metformin supply only for a territory where relevant exclusivity has ended. A live patent or exclusivity dispute on the requested presentation is not quoted. Glucophage is an originator name for identification only, not a Burrard trademark.
Burrard does not quote a molecule under a live patent or exclusivity dispute in the requested territory. Supply is discussed only where relevant exclusivity has ended.
Each link is a separate finished-dose programme with its own exclusivity note. Sitagliptin ยท Sitagliptin / metformin.
No. Burrard does not manufacture in-house. Manufacture is placed with a qualified partner GMP site named under CDA. The site is named in the quality pack after CDA.
No. This page does not claim FDA, EMA, or Health Canada product approval for metformin. The local MAH or importer holds destination marketing authorisation. Site GMP evidence is not product approval.
Oral solid, strengths confirmed under CDA. Pack size, stability zone, and CTD or ACTD status are not stated here.
Metformin is a long off-patent generic. This page does not say every salt, release profile, combination, or country is clear. Supply is discussed only where relevant exclusivity has ended. Combinations are out of scope on this page.
Email bd@burrardpharma.com with your company, territory, and whether you need finished-dose supply, dossier support, or both. The quality pack and a short supply call follow CDA.
Email bd@burrardpharma.com with company, territory, and finished-dose supply, dossier support, or both. You can also use the contact page.
For importers, distributors, and local marketing-authorisation holders only. Not patient information, not dosing guidance, and not an offer or a price. Burrard Pharmaceuticals Enterprises Ltd. does not manufacture in-house and does not claim FDA, EMA, or Health Canada product approval. Site GMP is not product approval. The local MAH or importer holds destination authorisation. Supply is discussed only where relevant exclusivity has ended. Strengths, packs, stability zones, and CTD status are confirmed under CDA, not here. Brand names are for identification only.